- Active, not recruiting
NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM
Updated: Oct 3, 2022
KarMMa
bb2121
NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

Relapsed & Refractory Myeloma
NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)
This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
Sponsor
Bristol Myers Squibb
ClinicalTrials.gov Identifier: NCT03361748
Official Title: A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
First Posted : December 5, 2017
Click here for details on ClinicalTrials.gov
CART - BCMA : National Cancer Institute
Idecabtagene Vicleucel : National Cancer Institute
Idecabtagene Vicleucel : MedlinePlus Drug Information
Anti-BCMA CAR T Cells BB2121